1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Company profile
Ticker
ATNF, ATNFW
Exchange
Website
CEO
Mr. Lloyd Blair Jordan L.L.B., M.B.A.
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
BAYVIEW ACQUISITION CORP
SEC CIK
Corporate docs
Subsidiaries
180 Life Corp. • Katexco Callco ULC • CannBioRex Callco ULC • 180 Therapeutics LP • Katexco Purchaseco ULC • CannBioRex Purchaseco ULC • Katexco Pharmaceuticals Corp. • CannBioRex Pharmaceuticals Corp. • CannBioRex Pharma Limited ...
ATNF stock data
Latest filings (excl ownership)
8-K
Unregistered Sales of Equity Securities
21 Oct 24
8-K
Entry into a Material Definitive Agreement
16 Oct 24
8-K
180 Life Sciences Corp. Interim CEO, Blair Jordan, Issues Letter to Stockholders; Provides Update on Newly Acquired Gaming Technology Platform
16 Oct 24
8-K
Other Events
9 Oct 24
8-K
180 Life Sciences Corp. – Corporate Updates
3 Oct 24
S-1/A
IPO registration (amended)
12 Sep 24
8-K
180 Life Sciences Announces the Appointment of Omar Jimenez as Chief Financial Officer
12 Sep 24
8-K
Entry into a Material Definitive Agreement
9 Sep 24
10-Q
2024 Q2
Quarterly report
12 Aug 24
8-K
Other Events
30 Jul 24
Latest ownership filings
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.15 mm | 1.15 mm | 1.15 mm | 1.15 mm | 1.15 mm | 1.15 mm |
Cash burn (monthly) | (no burn) | 71.86 k | 615.58 k | 1.50 mm | (no burn) | 353.48 k |
Cash used (since last report) | n/a | 269.84 k | 2.31 mm | 5.63 mm | n/a | 1.33 mm |
Cash remaining | n/a | 876.45 k | -1.17 mm | -4.49 mm | n/a | -181.04 k |
Runway (months of cash) | n/a | 12.2 | -1.9 | -3.0 | n/a | -0.5 |
Institutional ownership, Q2 2024
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 0 |
Closed positions | 6 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 15.85 mm |
Total shares | 4.30 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
KBL Iv Sponsor | 2.22 mm | $5.47 mm |
Bauer Ronald | 1.41 mm | $7.02 mm |
Bridgman Craig | 673.51 k | $3.36 mm |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Dec 23 | Marc Feldmann | Common Stock | Grant | Acquire A | No | No | 0 | 135,377 | 0.00 | 250,874 |
15 Dec 23 | James N. Woody | Common Stock | Buy | Acquire P | No | No | 0.188 | 25,000 | 4.70 k | 66,888 |
News
12 Health Care Stocks Moving In Thursday's Intraday Session
17 Oct 24
Dow Jumps Over 100 Points; Alcoa Profit Beats Estimates
17 Oct 24
12 Health Care Stocks Moving In Thursday's Pre-Market Session
17 Oct 24
Why TSMC Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
17 Oct 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
16 Oct 24
Press releases
180 Life Sciences Corp. Interim CEO, Blair Jordan, Issues Letter to Stockholders; Provides Update on Newly Acquired Gaming Technology Platform
16 Oct 24
180 Life Sciences Corp. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Rule and Expands into the Global iGaming Sector
9 Oct 24
180 Life Sciences Corp. - Corporate Updates
3 Oct 24
180 Life Sciences Announces the Appointment of Omar Jimenez as Chief Financial Officer
12 Sep 24